Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway

Indaptus Therapeutics, Inc.

R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).
Cash and marketable securities $26.4M as of Dec 31, 2022; runway into Q2 2024.
First patient dosed in Phase 1 Decoy20 trial for solid tumors in March 2023; three sites activated.
Net cash used in operations $13.1M for FY2022 vs $11.3M in FY2021.
Robert Martell, M.D., Ph.D. elected to Board in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Indaptus Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 17, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.